Crohn’s disease

Guselkumab for Crohn’s Disease and Ulcerative Colitis: Efficacy and Safety from Recent Phase 3 Trials

By MedXY 08/02/2025

Phase 3 studies demonstrate guselkumab's efficacy and safety as induction and maintenance therapy for moderate-to-severe Crohn's disease and ulcerative colitis, with superiority over placebo and favorable safety profiles.

Clinical Updates Wellness & Lifestyle

EASE-CD: A Validated Endoscopic Ulcer Activity Score for Crohn’s Disease—Clinical Utility and Evidence from Randomized Trials

By MedXY 08/02/2025

The EASE-CD index offers a reliable, validated, and responsive tool for quantifying Crohn's disease ulcer activity in clinical trials and practice, improving upon prior endoscopic indices.

Clinical Updates Wellness & Lifestyle

Targeting TL1A in IBD: Safety and Efficacy of Tulisokibart in Crohn’s Disease and Ulcerative Colitis—Emerging Phase 2 Data

By MedXY 08/02/2025

Phase 2 trials show anti-TL1A antibody tulisokibart offers potential efficacy and good tolerability in refractory Crohn’s disease and ulcerative colitis, with ongoing phase 3 studies to confirm findings.